Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034

(2016) Neil P. Shah et al.   AMERICAN JOURNAL OF HEMATOLOGY

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

(2016) Charles A. Schiffer et al.   CANCER

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

(2016) J L Steegmann et al.   LEUKEMIA

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

(2015) Neil P. Shah et al.   AMERICAN JOURNAL OF HEMATOLOGY

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia

(2015) Masatomo Miura   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia

(2015) Toshihiko Ando et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

(2015) T P Hughes et al.   LEUKEMIA

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

(2014) N. P. Shah et al.   BLOOD

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Large granular lymphocytosis during dasatinib therapy

(2013) Zhi-Yuan Qiu et al.   CANCER BIOLOGY & THERAPY

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up

(2013) Shin Fujisawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

(2013) Charles T. Chuah et al.   LEUKEMIA & LYMPHOMA

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

(2012) J. P. Radich et al.   BLOOD

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

(2012) S Mustjoki et al.   LEUKEMIA

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

(2011) H. M. Kantarjian et al.   BLOOD

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

(2010) Fabio P. S. Santos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study

(2010) Giuseppe Saglio et al.   CANCER

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

(2009) A. Quintas-Cardama et al.   BLOOD

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

(2009) Kimmo Porkka et al.   CANCER

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

(2008) D. H. Kim et al.   HAEMATOLOGICA

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia

(2008) Shaoguang Li   LEUKEMIA & LYMPHOMA